Triple

T17871590
Position Surface form Disambiguated ID Type / Status
Subject Amvuttra E446848 entity
Predicate hasInternationalNonproprietaryName P24556 FINISHED
Object vutrisiran NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: vutrisiran | Statement: [Amvuttra, hasInternationalNonproprietaryName, vutrisiran]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: vutrisiran
Context triple: [Amvuttra, hasInternationalNonproprietaryName, vutrisiran]
  • A. AMVUTTRA (vutrisiran) chosen
    AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
  • B. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • C. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • D. inotersen
    Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
  • E. GIVLAARI (givosiran)
    GIVLAARI (givosiran) is an RNA interference (RNAi) therapeutic used to reduce the frequency of attacks in adults with acute hepatic porphyria.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8b9f4c22c819093c2680434472894 completed April 10, 2026, 8:51 a.m.
NER Named-entity recognition batch_69e49aa30ff8819090c51c1d7767e952 completed April 19, 2026, 9:04 a.m.
Created at: April 10, 2026, 10:18 a.m.